A phase I trial to evaluate the safety and pharmacokinetics of low-dose methotrexate as an anti-malarial drug in Kenyan adult healthy volunteers.
BACKGROUND: Previous investigations indicate that methotrexate, an old anticancer drug, could be used at low doses to treat malaria. A phase I evaluation was conducted to assess the safety and pharmacokinetic profile of this drug in healthy adult male Kenyan volunteers. METHODS: Twenty five healthy...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
BioMed Central
2011
|
| _version_ | 1797067361972387840 |
|---|---|
| author | Chilengi, R Juma, R Abdallah, A Bashraheil, M Lodenyo, H Nyakundi, P Anabwani, E Salim, A Mwambingu, G Wenwa, E Jemutai, J Kipkeu, C Oyoo, G Muchohi, SN Kokwaro, G Niehues, T Lang, T Nzila, A |
| author_facet | Chilengi, R Juma, R Abdallah, A Bashraheil, M Lodenyo, H Nyakundi, P Anabwani, E Salim, A Mwambingu, G Wenwa, E Jemutai, J Kipkeu, C Oyoo, G Muchohi, SN Kokwaro, G Niehues, T Lang, T Nzila, A |
| author_sort | Chilengi, R |
| collection | OXFORD |
| description | BACKGROUND: Previous investigations indicate that methotrexate, an old anticancer drug, could be used at low doses to treat malaria. A phase I evaluation was conducted to assess the safety and pharmacokinetic profile of this drug in healthy adult male Kenyan volunteers. METHODS: Twenty five healthy adult volunteers were recruited and admitted to receive a 5 mg dose of methotrexate/day/5 days. Pharmacokinetics blood sampling was carried out at 2, 4, 6, 12 and 24 hours following each dose. Nausea, vomiting, oral ulcers and other adverse events were solicited during follow up of 42 days. RESULTS: The mean age of participants was 23.9 ± 3.3 years. Adherence to protocol was 100%. No grade 3 solicited adverse events were observed. However, one case of transiently elevated liver enzymes, and one serious adverse event (not related to the product) were reported. The maximum concentration (C(max)) was 160-200 nM and after 6 hours, the effective concentration (C(eff)) was <150 nM. CONCLUSION: Low-dose methotraxate had an acceptable safety profile. However, methotrexate blood levels did not reach the desirable C(eff) of 250-400-nM required to clear malaria infection in vivo. Further dose finding and safety studies are necessary to confirm suitability of this drug as an anti-malarial agent. |
| first_indexed | 2024-03-06T21:55:12Z |
| format | Journal article |
| id | oxford-uuid:4cadebce-2890-4af7-8e84-6e800f0a107a |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T21:55:12Z |
| publishDate | 2011 |
| publisher | BioMed Central |
| record_format | dspace |
| spelling | oxford-uuid:4cadebce-2890-4af7-8e84-6e800f0a107a2022-03-26T15:50:54ZA phase I trial to evaluate the safety and pharmacokinetics of low-dose methotrexate as an anti-malarial drug in Kenyan adult healthy volunteers.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:4cadebce-2890-4af7-8e84-6e800f0a107aEnglishSymplectic Elements at OxfordBioMed Central2011Chilengi, RJuma, RAbdallah, ABashraheil, MLodenyo, HNyakundi, PAnabwani, ESalim, AMwambingu, GWenwa, EJemutai, JKipkeu, COyoo, GMuchohi, SNKokwaro, GNiehues, TLang, TNzila, A BACKGROUND: Previous investigations indicate that methotrexate, an old anticancer drug, could be used at low doses to treat malaria. A phase I evaluation was conducted to assess the safety and pharmacokinetic profile of this drug in healthy adult male Kenyan volunteers. METHODS: Twenty five healthy adult volunteers were recruited and admitted to receive a 5 mg dose of methotrexate/day/5 days. Pharmacokinetics blood sampling was carried out at 2, 4, 6, 12 and 24 hours following each dose. Nausea, vomiting, oral ulcers and other adverse events were solicited during follow up of 42 days. RESULTS: The mean age of participants was 23.9 ± 3.3 years. Adherence to protocol was 100%. No grade 3 solicited adverse events were observed. However, one case of transiently elevated liver enzymes, and one serious adverse event (not related to the product) were reported. The maximum concentration (C(max)) was 160-200 nM and after 6 hours, the effective concentration (C(eff)) was <150 nM. CONCLUSION: Low-dose methotraxate had an acceptable safety profile. However, methotrexate blood levels did not reach the desirable C(eff) of 250-400-nM required to clear malaria infection in vivo. Further dose finding and safety studies are necessary to confirm suitability of this drug as an anti-malarial agent. |
| spellingShingle | Chilengi, R Juma, R Abdallah, A Bashraheil, M Lodenyo, H Nyakundi, P Anabwani, E Salim, A Mwambingu, G Wenwa, E Jemutai, J Kipkeu, C Oyoo, G Muchohi, SN Kokwaro, G Niehues, T Lang, T Nzila, A A phase I trial to evaluate the safety and pharmacokinetics of low-dose methotrexate as an anti-malarial drug in Kenyan adult healthy volunteers. |
| title | A phase I trial to evaluate the safety and pharmacokinetics of low-dose methotrexate as an anti-malarial drug in Kenyan adult healthy volunteers. |
| title_full | A phase I trial to evaluate the safety and pharmacokinetics of low-dose methotrexate as an anti-malarial drug in Kenyan adult healthy volunteers. |
| title_fullStr | A phase I trial to evaluate the safety and pharmacokinetics of low-dose methotrexate as an anti-malarial drug in Kenyan adult healthy volunteers. |
| title_full_unstemmed | A phase I trial to evaluate the safety and pharmacokinetics of low-dose methotrexate as an anti-malarial drug in Kenyan adult healthy volunteers. |
| title_short | A phase I trial to evaluate the safety and pharmacokinetics of low-dose methotrexate as an anti-malarial drug in Kenyan adult healthy volunteers. |
| title_sort | phase i trial to evaluate the safety and pharmacokinetics of low dose methotrexate as an anti malarial drug in kenyan adult healthy volunteers |
| work_keys_str_mv | AT chilengir aphaseitrialtoevaluatethesafetyandpharmacokineticsoflowdosemethotrexateasanantimalarialdruginkenyanadulthealthyvolunteers AT jumar aphaseitrialtoevaluatethesafetyandpharmacokineticsoflowdosemethotrexateasanantimalarialdruginkenyanadulthealthyvolunteers AT abdallaha aphaseitrialtoevaluatethesafetyandpharmacokineticsoflowdosemethotrexateasanantimalarialdruginkenyanadulthealthyvolunteers AT bashraheilm aphaseitrialtoevaluatethesafetyandpharmacokineticsoflowdosemethotrexateasanantimalarialdruginkenyanadulthealthyvolunteers AT lodenyoh aphaseitrialtoevaluatethesafetyandpharmacokineticsoflowdosemethotrexateasanantimalarialdruginkenyanadulthealthyvolunteers AT nyakundip aphaseitrialtoevaluatethesafetyandpharmacokineticsoflowdosemethotrexateasanantimalarialdruginkenyanadulthealthyvolunteers AT anabwanie aphaseitrialtoevaluatethesafetyandpharmacokineticsoflowdosemethotrexateasanantimalarialdruginkenyanadulthealthyvolunteers AT salima aphaseitrialtoevaluatethesafetyandpharmacokineticsoflowdosemethotrexateasanantimalarialdruginkenyanadulthealthyvolunteers AT mwambingug aphaseitrialtoevaluatethesafetyandpharmacokineticsoflowdosemethotrexateasanantimalarialdruginkenyanadulthealthyvolunteers AT wenwae aphaseitrialtoevaluatethesafetyandpharmacokineticsoflowdosemethotrexateasanantimalarialdruginkenyanadulthealthyvolunteers AT jemutaij aphaseitrialtoevaluatethesafetyandpharmacokineticsoflowdosemethotrexateasanantimalarialdruginkenyanadulthealthyvolunteers AT kipkeuc aphaseitrialtoevaluatethesafetyandpharmacokineticsoflowdosemethotrexateasanantimalarialdruginkenyanadulthealthyvolunteers AT oyoog aphaseitrialtoevaluatethesafetyandpharmacokineticsoflowdosemethotrexateasanantimalarialdruginkenyanadulthealthyvolunteers AT muchohisn aphaseitrialtoevaluatethesafetyandpharmacokineticsoflowdosemethotrexateasanantimalarialdruginkenyanadulthealthyvolunteers AT kokwarog aphaseitrialtoevaluatethesafetyandpharmacokineticsoflowdosemethotrexateasanantimalarialdruginkenyanadulthealthyvolunteers AT niehuest aphaseitrialtoevaluatethesafetyandpharmacokineticsoflowdosemethotrexateasanantimalarialdruginkenyanadulthealthyvolunteers AT langt aphaseitrialtoevaluatethesafetyandpharmacokineticsoflowdosemethotrexateasanantimalarialdruginkenyanadulthealthyvolunteers AT nzilaa aphaseitrialtoevaluatethesafetyandpharmacokineticsoflowdosemethotrexateasanantimalarialdruginkenyanadulthealthyvolunteers AT chilengir phaseitrialtoevaluatethesafetyandpharmacokineticsoflowdosemethotrexateasanantimalarialdruginkenyanadulthealthyvolunteers AT jumar phaseitrialtoevaluatethesafetyandpharmacokineticsoflowdosemethotrexateasanantimalarialdruginkenyanadulthealthyvolunteers AT abdallaha phaseitrialtoevaluatethesafetyandpharmacokineticsoflowdosemethotrexateasanantimalarialdruginkenyanadulthealthyvolunteers AT bashraheilm phaseitrialtoevaluatethesafetyandpharmacokineticsoflowdosemethotrexateasanantimalarialdruginkenyanadulthealthyvolunteers AT lodenyoh phaseitrialtoevaluatethesafetyandpharmacokineticsoflowdosemethotrexateasanantimalarialdruginkenyanadulthealthyvolunteers AT nyakundip phaseitrialtoevaluatethesafetyandpharmacokineticsoflowdosemethotrexateasanantimalarialdruginkenyanadulthealthyvolunteers AT anabwanie phaseitrialtoevaluatethesafetyandpharmacokineticsoflowdosemethotrexateasanantimalarialdruginkenyanadulthealthyvolunteers AT salima phaseitrialtoevaluatethesafetyandpharmacokineticsoflowdosemethotrexateasanantimalarialdruginkenyanadulthealthyvolunteers AT mwambingug phaseitrialtoevaluatethesafetyandpharmacokineticsoflowdosemethotrexateasanantimalarialdruginkenyanadulthealthyvolunteers AT wenwae phaseitrialtoevaluatethesafetyandpharmacokineticsoflowdosemethotrexateasanantimalarialdruginkenyanadulthealthyvolunteers AT jemutaij phaseitrialtoevaluatethesafetyandpharmacokineticsoflowdosemethotrexateasanantimalarialdruginkenyanadulthealthyvolunteers AT kipkeuc phaseitrialtoevaluatethesafetyandpharmacokineticsoflowdosemethotrexateasanantimalarialdruginkenyanadulthealthyvolunteers AT oyoog phaseitrialtoevaluatethesafetyandpharmacokineticsoflowdosemethotrexateasanantimalarialdruginkenyanadulthealthyvolunteers AT muchohisn phaseitrialtoevaluatethesafetyandpharmacokineticsoflowdosemethotrexateasanantimalarialdruginkenyanadulthealthyvolunteers AT kokwarog phaseitrialtoevaluatethesafetyandpharmacokineticsoflowdosemethotrexateasanantimalarialdruginkenyanadulthealthyvolunteers AT niehuest phaseitrialtoevaluatethesafetyandpharmacokineticsoflowdosemethotrexateasanantimalarialdruginkenyanadulthealthyvolunteers AT langt phaseitrialtoevaluatethesafetyandpharmacokineticsoflowdosemethotrexateasanantimalarialdruginkenyanadulthealthyvolunteers AT nzilaa phaseitrialtoevaluatethesafetyandpharmacokineticsoflowdosemethotrexateasanantimalarialdruginkenyanadulthealthyvolunteers |